A randomized prospective study to evaluate the efficacy of various topical treatment modalities in patients of alopecia areata

Nagendra S. Manthale, Dayanand R. Raikar, Shrinivas R. Raikar


Background:Alopecia areata (AA) is one of the common causes of localized hair loss among the patients attending the outpatient department. The objective of this study was to know the clinical and epidemiological profile of AA and to compare the efficacy of different topical treatment modalities in AA.

Methods:100 patients of any age group and of both sexes presenting with AA to the dermatology outpatient department were included in this study. It was conducted as a randomized prospective study for a period of 12 weeks after taking an informed consent from the patient. After studying the clinical profile, patients were randomly distributed, excluding the age and sex bias into four treatment groups. Alopecia grading scale (AGS) was calculated at first visit and 12 weeks. Regrowth score (RGS) was calculated at 12 weeks. Treatment outcome in different groups were compared using mean AGS at 12 weeks and RGS.

Results:Group A patients showed statistically significant clinical improvement when compared to all the other groups. Poorest response was seen in Group D. Intermediate response was seen in Group B and C patients.

Conclusions:The study concluded that topical 0.05% betamethasone dipropionate is the most effective treatment modality in patients with patchy AA (having <25% hair loss).


Alopecia areata, Betamethasone dipropionate, Minoxidil, Anthralin, Tacrolimus

Full Text:



Ebstein E. Evidence based treatment of alopecia areata. J Am Acad Dermatol. 2001;45:640-2.

Ioffreda MD. Inflammatory Diseases of Hair Follicles, Sweat Glands, and Cartilage. In: Elder DE, Elenitsas R, Johnson BL, Murphy GF, Xu X. Lever’S Histopathology of the Skin. 10th ed. Philadelphia: Lippincott Williams and Wilkins; 2009: 474-475.

Seyrafi H, Akhiani M, Abbasi H, Mirpour S, Gholamrezanezhad A. Evaluation of the profile of alopecia areata and the prevalence of thyroid function test abnormalities and serum autoantibodies in Iranian patients. BMC Dermatol. 2005;5:11.

Price VH, Colombe BW. Heritable factors distinguish two types of alopecia areata. Dermatol Clin. 1996;14:679-89.

Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol, 1992;128(5):702.

Awachat AK, Sharma ML, Rao MS. Alopecia Areata. Indian J Dermatol Venereol. 1960;26:59-70.

Zappacosta AR. Reversal of baldness in a patient receiving minoxidil for hypertension. N Engl J Med. 1980;303:1480-1.

Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A. Alopecia areata. Int J Dermatol. 2007;46:121-31.

Majid I, Keen A. Management of alopecia areata: an update. British J Med Practitioners. 2012;5(3):14-20.

Mandani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42:549-66.

Sardesai VR, Prasad S, Agarwal TD. A Study to Evaluate the Efficacy of Various Topical Treatment Modalities for Alopecia Areata. Int J Trichol. 2012;4(4):265-70.

Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in northern India. Int J Dermatol. 1996;35:22-7.

Das S, Ghorami RC, Chatterjee T and Banerjee G. Comparative Assessment of Topical Steroids, Topical Tretinoin (0.05%) and Dithranol paste in Alopecia Areata. Indian J Dermatol. 2010;55(2):148-9.

Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol. 1987;16 (3):730-6.

Fiedler-Weiss VC, Buys CM. Evaluation of Anthralin in the Treatment of Alopecia Areata. Arch Dermatol. 1987;123(11):1491-3.

Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol. 2005;52(1):138-9.